Journal of Inherited Metabolic Disease

, Volume 31, Issue 1, pp 7–20

Interpretation of plasma amino acids in the follow-up of patients: The impact of compartmentation

EMG Lecture


Results of plasma or urinary amino acids are used for suspicion, confirmation or exclusion of diagnosis, monitoring of treatment, prevention and prognosis in inborn errors of amino acid metabolism. The concentrations in plasma or whole blood do not necessarily reflect the relevant metabolite concentrations in organs such as the brain or in cell compartments; this is especially the case in disorders that are not solely expressed in liver and/or in those which also affect nonessential amino acids. Basic biochemical knowledge has added much to the understanding of zonation and compartmentation of expressed proteins and metabolites in organs, cells and cell organelles. In this paper, selected old and new biochemical findings in PKU, urea cycle disorders and nonketotic hyperglycinaemia are reviewed; the aim is to show that integrating the knowledge gained in the last decades on enzymes and transporters related to amino acid metabolism allows a more extensive interpretation of biochemical results obtained for diagnosis and follow-up of patients and may help to pose new questions and to avoid pitfalls. The analysis and interpretation of amino acid measurements in physiological fluids should not be restricted to a few amino acids but should encompass the whole quantitative profile and include other pathophysiological markers. This is important if the patient appears not to respond as expected to treatment and is needed when investigating new therapies. We suggest that amino acid imbalance in the relevant compartments caused by over-zealous or protocol-driven treatment that is not adjusted to the individual patient’s needs may prolong catabolism and must be corrected.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Appel SH (1966) Inhibition of brain protein synthesis: an approach to the biochemical basis of neurological dysfunction in the amino-acidurias. Trans N Y Acad Sci 29: 63–70.PubMedGoogle Scholar
  2. Applegarth DA, Toone JR (2001) Nonketotic hyperglycinemia (glycine encephalopathy): laboratory diagnosis. Mol Genet Metab 74: 139–146.PubMedCrossRefGoogle Scholar
  3. Bachmann C (1992) Ornithine carbamoyl transferase deficiency: findings, models and problems. J Inherit Metab Dis 15: 578–591.PubMedCrossRefGoogle Scholar
  4. Bachmann C (2002) Mechanisms of hyperammonemia. Clin Chem Lab Med 40: 653–662.PubMedCrossRefGoogle Scholar
  5. Bachmann C (2007) Hyperammonemia: Review of current treatment strategies. In: Bachmann C, Häberle J, Leonard J, eds. Pathophysiology and Management of Hyperammonaemia. Heilbronn: SPS Verlagsgesellschaft, 157–173.Google Scholar
  6. Bachmann C, Mihatsch MJ, Baumgartner RE et al (1971) Non-ketotic hyperglycinemia: peracute course in neonatal period. Helv Paediatr Acta 26: 228–243.PubMedGoogle Scholar
  7. Bak LK, Schousboe A, Waagepetersen HS (2006) The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem 98: 641–653.PubMedCrossRefGoogle Scholar
  8. Batshaw ML, MacArthur RB, Tuchman M (2001) Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 138: S46–54; discussion S54–45.PubMedCrossRefGoogle Scholar
  9. Berger V, Larondelle Y, Trouet A, Schneider YJ (2000) Transport mechanisms of the large neutral amino acid l-phenylalanine in the human intestinal epithelial Caco-2 cell line. J Nutr 130: 2780–2788.PubMedGoogle Scholar
  10. Bhattacharya K, Briddon A, Lee P (2007) A review of biochemical outcomes of adults with OTC deficiency. J Inherit Metab Dis 30: 82.CrossRefGoogle Scholar
  11. Bixel MG, Shimomura Y, Hutson SM, Hamprecht B (2001) Distribution of key enzymes of branched-chain amino acid metabolism in glial and neuronal cells in culture. J Histochem Cytochem 49: 407–418.PubMedGoogle Scholar
  12. Blaheta RA, Cinatl J Jr (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22: 492–511.PubMedCrossRefGoogle Scholar
  13. Brosnan JT, Brosnan ME (2006) Branched-chain amino acids: enzyme and substrate regulation. J Nutr 136: 207–211.Google Scholar
  14. Bruhat A, Jousse C, Fafournoux P (1999) Amino acid limitation regulates gene expression. Proc Nutr Soc 58: 625–632.PubMedGoogle Scholar
  15. Calvaruso G, Carabillo M, Giuliano M et al (2001) Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: the effect of combined treatment with the topoisomerase I-inhibitor topotecan. Int J Oncol 18: 1233–1237.PubMedGoogle Scholar
  16. Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG (2007) Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Investigational New Drugs 25: 131–138.PubMedCrossRefGoogle Scholar
  17. Chang TH, Szabo E (2002) Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 8: 1206–1212.PubMedGoogle Scholar
  18. Chang TW, Goldberg AL (1978) The origin of alanine produced in skeletal muscle. J Biol Chem 253: 3677–3684.PubMedGoogle Scholar
  19. Chen N, Reith M, Quick M (2004) Synaptic uptake and beyond: the sodium- and chloride dependent neurotransmitter transporter family SLC6. Pflügers Arch Eur J Physiol 447: 519–531.CrossRefGoogle Scholar
  20. Codogno P, Meijer AJ (2005) Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ 12: 1509–1518.PubMedCrossRefGoogle Scholar
  21. Curthoys NP, Watford M (1995) Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr 15: 133–159.PubMedCrossRefGoogle Scholar
  22. Darmaun D, Welch S, Rini A, Sager BK, Altomare A, Haymond MW (1998) Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism. Am J Physiol Endocrinol Metab 274: 801–807.Google Scholar
  23. Diezel PB, Martin K (1966) Hyperglycinemia (glycinosis) with familial idiopathic hyperglycinuria. 1st observation in Germany. Dtsch Med Wochenschr 91: 2249–2254.PubMedCrossRefGoogle Scholar
  24. Dingemanse MA, De Jonge WJ, De Boer PAJ, Mori M, Lamers WH, Moorman AF (1996) Development of the ornithine cycle in rat liver: Zonation of a metabolic pathway. Hepatology 24: 407–411.PubMedCrossRefGoogle Scholar
  25. Endo Y, Fu Z, Abe K, Arai S, Kato H (2002) Dietary protein quantity and quality affect rat hepatic gene expression 1. J Nutr 132: 3632–3637.PubMedGoogle Scholar
  26. Eulenburg V, Armsen W, Betz H, Gomeza J (2005) Glycine transporters: essential regulators of neurotransmission. Trends Biochem Sci 30: 325–333.PubMedCrossRefGoogle Scholar
  27. Gebhardt R, Baldysiak-Figiel A, Krugel V, Ueberham E, Gaunitz F (2007) Hepatocellular expression of glutamine synthetase: An indicator of morphogen actions as master regulators of zonation in adult liver. Prog Histochem Cytochem 41: 201–266.PubMedCrossRefGoogle Scholar
  28. Gitzelmann R, Steinmann B, Otten A et al (1978) Nonketotic hyperglycinemia treated with strychnine, a glycine receptor antagonist. Helv Paediatr Acta 32: 517–525.PubMedGoogle Scholar
  29. Gottlicher M (2004) Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hemat 83(Supplement 1): S91–92.Google Scholar
  30. Güttler F, Lou H (1986) Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. J Inherit Metab Dis 9: 169–177.PubMedCrossRefGoogle Scholar
  31. Hall TR, Wallin R, Reinhart GD, Hutson SM (1993) Branched chain aminotransferase isoenzymes. Purification and characterization of the rat brain isoenzyme. J Biol Chem 268: 3092–3098.PubMedGoogle Scholar
  32. Hankard RG, Darmaun D, Sager BK, D’Amore D, Parsons WR, Haymond M (1995) Response of glutamine metabolism to exogenous glutamine in humans. Am J Physiol Endocrinol Metab 269: 663–670.Google Scholar
  33. Harris DJ, Thompson RM, Wolf B, Yang BI (1981) Propionyl coenzyme A carboxylase deficiency presenting as non-ketotic hyperglycinaemia. J Med Genet 18: 156–157.CrossRefGoogle Scholar
  34. Harris TE, Chi A, Shabanowitz J, Hunt DF, Rhoads RE, Lawrence JC Jr (2006) mTOR-dependent stimulation of the association of eIF4G and eIF3 by insulin. EMBO J 25: 1659–1668.PubMedCrossRefGoogle Scholar
  35. Häussinger D (1983) Hepatocyte heterogeneity in glutamine and ammonia metabolism and the role of an intercellular glutamine cycle during ureogenesis in perfused rat liver. Eur J Biochem 133: 269–275.PubMedCrossRefGoogle Scholar
  36. Hawkins RA, O’Kane RL, Simpson IA, Vina JR (2006) Structure of the blood–brain barrier and its role in the transport of amino acids. J Nutr 136: 218–226.Google Scholar
  37. Huisman T, Thiel T, Steinmann B, Zeilinger G, Martin E (2002) Proton magnetic resonance spectroscopy of the brain of a neonate with nonketotic hyperglycinemia: in vivoin vitro (ex vivo) correlation. Eur Radiol 12: 858–861.PubMedCrossRefGoogle Scholar
  38. Hutson SM, Berkich D, Drown P, Xu B, Aschner M, LaNoue KF (1998) Role of branched-chain aminotransferase isoenzymes and gabapentin in neurotransmitter metabolism. J Neurochem 71: 863–874.PubMedCrossRefGoogle Scholar
  39. Hutson SM, Lieth E, LaNoue KF (2001) Function of leucine in excitatory neurotransmitter metabolism in the central nervous system. J Nutr 131: 846–850.Google Scholar
  40. Hutson SM, Wallin R, Hall TR (1992) Identification of mitochondrial branched chain aminotransferase and its isoforms in rat tissues. J Biol Chem 267: 15681–15686.PubMedGoogle Scholar
  41. Islam M, Wallin R, Wynn RM et al (2007) A novel branched-chain amino acid metabolon: protein–protein interactions in a supramolecular complex. J Biol Chem 282: 11893–11903.PubMedCrossRefGoogle Scholar
  42. Isojärvi J, Laatikainen TJ, Pakarinen AJ, Juntunen K, Myllylä VV (1993) Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329: 1383–1388.PubMedCrossRefGoogle Scholar
  43. Jones JG, Solomon MA, Sherry AD, Jeffrey FMH, Malloy CR (1998) 13C NMR measurements of human gluconeogenic fluxes after ingestion of [U-13C] propionate, phenylacetate, and acetaminophen. Am J Physiol Endocrinol Metab 275: 843–852.Google Scholar
  44. Jousse C, Bruhat A, Ferrara M, Fafournoux P (1998) Physiological concentration of amino acids regulates insulin-like-growth-factor-binding protein 1 expression. Biochem J 334: 147–153.PubMedGoogle Scholar
  45. Jungermann K, Kietzmann T (1996) Zonation of parenchymal and nonparenchymal metabolism in liver. Annu Rev Nutr 16: 179–203.PubMedCrossRefGoogle Scholar
  46. Kanai Y, Hediger MA (2004) The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects. Pflügers Arch Eur J Physiol 447: 469–479.CrossRefGoogle Scholar
  47. Kanamori K, Ross BD (2004) Quantitative determination of extracellular glutamine concentration in rat brain, and its elevation in vivo by system A transport inhibitor, alpha-(methylamino) isobutyrate. J Neurochem 90: 203–210.PubMedCrossRefGoogle Scholar
  48. Kanamori K, Ross BD (2005) Suppression of glial glutamine release to the extracellular fluid studied in vivo by NMR and microdialysis in hyperammonemic rat brain. J Neurochem 94: 74–85.PubMedCrossRefGoogle Scholar
  49. Kanamori K, Ross BD, Kondrat RW (1998) Rate of glutamate synthesis from leucine in rat brain measured in vivo by 15 N NMR. J Neurochem 70: 1304–1315.PubMedCrossRefGoogle Scholar
  50. Koch R, Moseley KD, Yano S, Nelson Jr M, Moats RA (2003) Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment. Mol Genet Metab 79: 110–113.PubMedCrossRefGoogle Scholar
  51. Korman SH, Gutman A (2002) Pitfalls in the diagnosis of glycine encephalopathy (non-ketotic hyperglycinemia). Dev Med Child Neurol 44: 712–720.PubMedCrossRefGoogle Scholar
  52. Labow BI, Souba WW, Abcouwer SF (2001) Mechanisms governing the expression of the enzymes of glutamine metabolism—glutaminase and glutamine synthetase. J Nutr 131: 2467S–2474S; discussion 2486S–2467S.PubMedGoogle Scholar
  53. Lea MA, Sura M, Desbordes C (2004) Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists. Anticancer Res 24: 2765–2771.PubMedGoogle Scholar
  54. Lee WJ, Hawkins RA, Peterson DR, Vina JR (1996) Role of oxoproline in the regulation of neutral amino acid transport across the blood–brain barrier. J Biol Chem 271: 19129.PubMedCrossRefGoogle Scholar
  55. Leweling H, Breitkreutz R, Behne F, Staedt U, Striebel JP, Holm E (1996) Hyperammonemia-induced depletion of glutamate and branched-chain amino acids in muscle and plasma. J Hepatol 25: 756–762.PubMedCrossRefGoogle Scholar
  56. Lou HC, Güttler F, Lykkelund C, Bruhn P, Niederwieser A (1985) Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents. Eur J Pediatr 144: 17–20.PubMedCrossRefGoogle Scholar
  57. Mackenzie B, Erickson JD (2004) Sodium-coupled neutral amino acid (System N/A) transporters of the SLC38 gene family. Pflügers Arch Eur J Physiol 447: 784–795.CrossRefGoogle Scholar
  58. Maestri NE, Clissold DB, Brusilow SW (1995) Long-term survival of patients with argininosuccinate synthetase deficiency. J Pediatr 127: 929–935.PubMedCrossRefGoogle Scholar
  59. Maestri NE, Clissold D, Brusilow SW (1999) Neonatal onset ornithine transcarbamylase deficiency: a retrospective analysis. J Pediatr 134: 268–272.PubMedCrossRefGoogle Scholar
  60. Marcaggi P, Coles JA (2001) Ammonium in nervous tissue: transport across cell membranes, fluxes from neurons to glial cells, and role in signalling. Prog Neurobiol 64: 157–183.PubMedCrossRefGoogle Scholar
  61. Matalon R, Surendran S, Matalon KM et al (2003) Future role of large neutral amino acids in transport of phenylalanine into the brain. Pediatr 112: 1570–1574.Google Scholar
  62. Matalon R, Michals-Matalon K, Bhatia G et al (2006) Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis 29: 732–738.PubMedCrossRefGoogle Scholar
  63. Matalon R, Michals-Matalon K, Bhatia G et al (2007) Double blind placebo control trial of large neutral amino acids in treatment of PKU: Effect on blood phenylalanine. J Inherit Metab Dis 30: 153–158.Google Scholar
  64. Mehnert JM, Kelly WK (2007) Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 13: 23–29.PubMedGoogle Scholar
  65. Meijer AJ, Dubbelhuis PF (2004) Amino acid signalling and the integration of metabolism. Biochem Biophys Res Commun 313: 397–403.PubMedCrossRefGoogle Scholar
  66. Miller LP, Pardridge WM, Braun LD, Oldendorf WH (1985) Kinetic constants for blood-brain barrier amino acid transport in conscious rats. J Neurochem 45: 1427–1432.PubMedCrossRefGoogle Scholar
  67. Miyanaka K, Gotoh T, Nagasaki A et al (1998) Immunohistochemical localization of arginase II and other enzymes of arginine metabolism in rat kidney and liver. Histochem J 30: 741–751.PubMedCrossRefGoogle Scholar
  68. Morris AAM, Leonard JV (1997) Early recognition of metabolic decompensation. Arch Dis Child 76: 555–556.PubMedGoogle Scholar
  69. Nishitani S, Ijichi C, Takehana K, Fujitani S, Sonaka I (2004) Pharmacological activities of branched-chain amino acids: specificity of tissue and signal transduction. Biochem Biophys Res Commun 313: 387–389.PubMedCrossRefGoogle Scholar
  70. Nissim I (1999) Newer aspects of glutamine/glutamate metabolism: the role of acute pH changes. Am J Physiol 277: 493–497.Google Scholar
  71. Novotny EJ, Fulbright RK, Pearl PL, Gibson KM, Rothman DL (2003) Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann Neurol 54: S25–S31.PubMedCrossRefGoogle Scholar
  72. Oldendorf WH, Sisson BW, Silverstein A (1971) Brain uptake of selenomethionine Se 75. II. Reduced brain uptake of selenomethionine Se 75 in phenylketonuria. Arch Neurol 24: 524–528.PubMedGoogle Scholar
  73. Orlowski J, Grinstein S (2004) Diversity of the mammalian sodium/proton exchanger SLC9 gene family. Pflügers Arch Eur J Physiol 447: 549–565.CrossRefGoogle Scholar
  74. Owen OE (1998) Protein, fat, and carbohydrate requirements during starvation: anaplerosis and cataplerosis]. J Nutr 68: 12–34.Google Scholar
  75. Palacin M, Yoshikatsu K (2004) The ancillary proteins of HATs: SLC3 family of amino acid transporters. Pflügers Arch Eur J Physiol 447: 490–494.CrossRefGoogle Scholar
  76. Palmieri F (2004) The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflügers Arch Eur J Physiol 447: 689–709.CrossRefGoogle Scholar
  77. Perry TL, Hansen S, Berry K, Mok C, Lesk D (1971) Free amino acids and related compounds in biopsies of human brain. J Neurochem 18: 521–528.PubMedCrossRefGoogle Scholar
  78. Perry TL, Urquhart N, MacLean J et al (1975) Nonketotic hyperglycinemia. Glycine accumulation due to absence of glycerine cleavage in brain. N Engl J Med 292: 1269–1273.PubMedCrossRefGoogle Scholar
  79. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734–36741.PubMedCrossRefGoogle Scholar
  80. Pichili VB, Rao KV, Jayakumar AR, Norenberg MD (2007) Inhibition of glutamine transport into mitochondria protects astrocytes from ammonia toxicity. Glia 55: 801–809.PubMedCrossRefGoogle Scholar
  81. Pietz J, Kreis R, Rupp A et al (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103: 1169–1178.PubMedCrossRefGoogle Scholar
  82. Plaitakis A, Spanaki C, Mastorodemos V, Zaganas I (2003) Study of structure-function relationships in human glutamate dehydrogenases reveals novel molecular mechanisms for the regulation of the nerve tissue-specific (GLUD2) isoenzyme. Neurochem Int 43: 401–410.PubMedCrossRefGoogle Scholar
  83. Proud CG (2004a) mTOR-mediated regulation of translation factors by amino acids. Biochem Biophys Res Commun 313: 429–436.CrossRefGoogle Scholar
  84. Proud CG (2004b) Role of mTOR signalling in the control of translation initiation and elongation by nutrients. Curr Top Microbiol Immunol 279: 215–244.Google Scholar
  85. Rennie MJ, Wackerhage H, Spangenburg EE, Booth FW (2004) Control of the size of the human muscle mass. Ann Rev Physiol 66: 799–828.CrossRefGoogle Scholar
  86. Scaglia F, Carter S, O’Brien WE, Lee B (2004) Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol Genet Metab 81: S79–85.PubMedCrossRefGoogle Scholar
  87. Scaglia F, Lanpher B, Marinim J, Lee B (2007) Role of branched chain amino acids in patients with urea cycle disorders. In: Bachmann C, Häberle J, Leonard J, eds. Pathophysiology and Management of Hyperammonaemia. Heilbronn: SPS Verlagsgesellschaft, 157–173.Google Scholar
  88. Shih V (2003) Amino acid analysis. In: Blau N, Duran M, Blaskovics M, Gibson M, eds. Physician’s Guide to the Laboratory Diagnosis of Metabolic Diseases. Berlin: Springer-Verlag, 11–26.Google Scholar
  89. Summar M (2001) Current strategies for the management of neonatal urea cycle disorders. J Pediatr 138: S30–39.PubMedCrossRefGoogle Scholar
  90. Sweatt AJ, Garcia-Espinosa MA, Wallin R, Hutson SM (2004) Branched-chain amino acids and neurotransmitter metabolism: Expression of cytosolic branched-chain aminotransferase(BCATc) in the cerebellum and hippocampus. J Comp Neurol 477: 360–370.PubMedCrossRefGoogle Scholar
  91. Tada K, Kure S (2005) Nonketotic hyperglycinemia: Pathophysiological studies. Proc Japan Acad 81: 411–417.CrossRefGoogle Scholar
  92. Taub F, Johnson TC (1975) The mechanism of polyribosome disaggregation in brain tissue by phenylalanine. Biochem J 151: 173–180.PubMedGoogle Scholar
  93. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y (2004) CATs and HATs: the SLC7 family of amino acid transporters. Pflügers Arch Eur J Physiol 447: 532–542.CrossRefGoogle Scholar
  94. von Wendt L, Simila S, Saukkonen AL, Koivisto M (1980) Failure of strychnine treatment during the neonatal period in three Finnish children with nonketotic hyperglycinemia. Pediatrics 65: 1166–1169.Google Scholar
  95. Welbourne TC (1987) Interorgan glutamine flux in metabolic acidosis. Am J Physiol 253: F1069-1076.Google Scholar
  96. Whitehead KJ, Pearce SM, Walker G, Sundaram H, Hill D, Bowery NG (2004) Positive N-methyl-d-aspartate receptor modulation by selective glycine transporter-1 inhibition in the rat dorsal spinal cord in vivo. Neuroscience 126: 381–390.PubMedCrossRefGoogle Scholar
  97. Wilson CJ, Lee PJ, Leonard JV (2001) Plasma glutamine and ammonia concentrations in ornithine carbamoyltransferase deficiency and citrullinaemia. J Inherit Metab Dis 24: 691–695.PubMedCrossRefGoogle Scholar
  98. Xin X, Yang S, Kowalski J, Gerritsen ME (1999) Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274: 9116–9121.PubMedCrossRefGoogle Scholar
  99. Yoshizawa F (2004) Regulation of protein synthesis by branched-chain amino acids in vivo. Biochem Biophys Res Commun 313: 417–422.PubMedCrossRefGoogle Scholar
  100. Yudkoff M, Daikhin Y, Nissim I et al (2005) Brain amino acid requirements and toxicity: the example of leucine. JNutr 135: 1531–1538.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  1. 1.Clinical ChemistryUniversity of LausanneLausanneSwitzerland
  2. 2.BottmingenSwitzerland

Personalised recommendations